13 October, 2026 | Jabbar Ali - MPharm
If you're on Mounjaro and you've started wondering whether to stop, you're asking a fair and very common question. Maybe you've reached a weight you're happy with, maybe the cost is adding up, or maybe you're just not sure you want to be on this medicine long term. Whatever the reason, it's worth understanding what the evidence actually shows before you change anything.
This article explains what happens to your weight when treatment stops, what happens if you lower the dose instead, and how our UK-based clinical team can help you weigh up your options.
There's no shame in wanting to stop. A lot of people reach a point where they feel they've done the hard part and want to see if they can hold their weight on their own. Others are weighing up the monthly cost, or they've come off treatment because of how they access it rather than because they chose to.
The honest answer is that whether stopping is right for you is a clinical decision, and it depends on your individual health, not on willpower. What the evidence can do is tell you what tends to happen, so you can make that decision with your eyes open.
To understand the trial results, it helps to understand how doctors now think about obesity. It's viewed as a chronic, relapsing condition driven by biology, not simply a matter of eating less and moving more.
When you lose weight, your body works to defend its previous weight. Hunger signals increase, the body uses less energy, and interest in food rises. This is biology doing its job, and it's the reason weight lost through dieting alone so often returns.
Medicines like Mounjaro (the active ingredient is trizepatide) work on that biology. Tirzepatide acts on two gut-hormone receptors, GLP-1 and GIP, including receptors in the brain linked to appetite. That's why it can reduce the constant pull towards food that many people describe. And it's also why the question of what happens when you stop matters as much as how well it works while you're taking it. If the medicine is managing the biology, removing it tends to let the biology reassert itself.
Three trials in the SURMOUNT programme help answer this.
SURMOUNT-1 was the main study of how much weight people lose. Over 72 weeks, in 2,539 adults with obesity who did not have type 2 diabetes, average weight loss was 2.4% on placebo, 16.0% on the 5mg dose, 21.4% on 10mg and 22.5% on 15mg.
On the highest dose, 96% of people lost more than 5% of their body weight and 62% lost more than 20%.
A small group, around 3.7%, didn't lose more than 5%, and researchers framed this as a difference in disease biology rather than a lack of effort.
SURMOUNT-4 asked the more relevant question for anyone thinking of stopping: what happens when treatment is withdrawn?
People were built up to their dose, then some continued the medicine and some switched to a placebo. Everyone kept the same diet, exercise and medical support. The people who stayed on treatment held on to their weight loss. The people who switched to a placebo began to regain weight, despite doing everything else right.
The interpretation was that this isn't a loss of motivation. It's the underlying condition returning once the biological treatment is removed.
The practical takeaway is that the evidence doesn't support thinking of Mounjaro as a short "kickstart" you can stop once you hit your goal. For many people, ongoing treatment is what maintains the result.
This is where the newest evidence, SURMOUNT-MAINTAIN, adds something. It looked at people who had already reached their lowest weight, then either stayed on their maximum tolerated dose, stepped down to 5mg, or switched to placebo.
The pattern was consistent. People who stayed on the higher dose largely kept their results. People who dropped to 5mg didn't hold the full benefit; they tended to drift towards the level of weight loss you'd expect from 5mg in the first place. People on placebo regained the most. The same pattern showed up in health markers, not just the scales, including waist measurement, HbA1c (a blood-sugar marker) and blood pressure.
So lowering the dose isn't a neutral halfway house. It tends to move you towards the result that dose would have given you on its own. That doesn't make a lower dose wrong. For some people it's the right balance of benefit and cost, which is a genuine consideration.
Some clinicians talk about a "maximum affordable dose", meaning the dose you can sustain long term rather than the highest one you could tolerate, on the basis that a lower dose you stay on may do more good than a higher dose you have to stop. The point is that this is a conversation to have with your prescriber, not a change to make on your own.
Not sure whether to stop, lower your dose, or stay as you are? Our UK-based clinical team can talk it through with you and look at what fits your health and your budget.
This one causes a lot of unnecessary stopping, so it's worth understanding.
Many people notice the biggest drop in "food noise", that constant background thinking about food, in the first few months, roughly between weeks 4 and 24. Around this time it can feel like a switch has flipped.
Later on, often around the point your weight settles, some of that hunger comes back and you start thinking about food more again. It's easy to read this as the medicine failing. Usually it isn't. It's more likely to be your appetite returning as your body reaches a new, lower, settled weight.
Two better signals of whether treatment is working are your weight and your health markers, not how hungry you feel on a given day. Chasing away every hint of hunger by changing the dose isn't the aim, and clinicians generally advise against it.
Reaching a plateau isn't a sign you've done something wrong either. It's the body settling, and it's expected.
There's no fixed answer, and anyone who gives you a guaranteed one is overpromising. Because obesity is treated as a long-term condition, the honest framing many clinicians use is that treatment continues for as long as you want to keep the condition managed, in the same way blood pressure medication continues while it's doing its job. That doesn't mean you can never stop. It means stopping is a decision to plan with a clinician, so you know what to expect and can act early if your weight or appetite starts to change.
The most important thing is not to stop or change your dose suddenly on your own. Talk to your prescriber first, so you can plan it properly and know what to watch for.
If you do stop, it helps to know that appetite tends to return within a couple of weeks. Why? Because after two weeks, roughly a quarter of the dose remains. After five weeks, your body is completely clear of the dose.
If your weight stays stable and your appetite stays settled, that's a good sign. If you notice hunger climbing again, that's usually the earliest signal the condition is returning, and it's worth speaking to your clinician sooner rather than later rather than waiting for the weight to come back.
The evidence suggests most people regain a significant amount of weight after stopping, even with good diet and exercise, because obesity is a long-term condition that tends to return once treatment stops. How much and how fast varies between individuals. Speak to your prescriber before stopping so you can plan it.
You can discuss a lower dose with your prescriber, and for some people it's a sensible, sustainable choice. But the evidence shows a lower dose tends to hold less of your weight loss, so it's a trade-off to make with clinical advice, not on your own.
Not necessarily. Some appetite often returns as your weight settles, and this is usually normal rather than a sign of failure. Your weight and health markers are better guides to whether treatment is working. Don't change your dose without speaking to your clinician.
Don't make sudden changes without medical advice. Talk to your prescriber so any change is planned and monitored, particularly if you take other medicines or have another health condition.
There's no fixed timeframe. Because obesity is treated as a chronic condition, many people stay on treatment while it's needed, but stopping can be planned with a clinician when it's right for you.
Deciding whether to continue, lower your dose or stop isn't something you have to work out alone, and it isn't a test of willpower. What the evidence shows is that these are genuine clinical trade-offs, and the right answer depends on you.
“Wanting to stop is completely understandable, and it's a decision we're glad to have with our patients rather than have them make alone. What the evidence tells us is that obesity behaves like other long-term conditions, so the plan for stopping or lowering a dose matters as much as the decision itself.”
Omar El-Gohary, Superintendent Pharmacist, iQ Doctor
iQ Doctor is a UK-based, fully licensed, GPhC-registered online pharmacy, and our UK-based clinical team is here to help you make sense of your options and support you whatever you decide. If you're weighing up a change to your treatment, the best next step is a conversation.
This page has been written by a registered UK pharmacist and reviewed by our clinical team to ensure it is accurate, clear and reflects current clinical guidance.
Last medically reviewed: 13 October, 2026
Last updated: 13 October, 2026